ClinicalTrials.gg
CompletedNCT01563367CABG-01Updated Apr 29, 2014

A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof

A Phase 3 interventional study of Iron isomaltoside 1000 (Monofer®) and Natriumklorid 9 mg/ml, Fresenius Kabi in Non-anaemic Patients Undergoing Cardiac Surgery, sponsored by Pharmacosmos A/S. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by Pharmacosmos A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing iron isomaltoside 1000 in Anemia — 12 open to participants now, 12 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia.

Enrollment
20th of 29
74 · median 120
Started
2012
with 2 others
Phase 3
9 of 29
4 open now
Registered
5th of 29
by date
Lead sponsor
6 of 29
Pharmacosmos A/S

Among the 29 studies testing iron isomaltoside 1000 in Anemia, this one is the 20th largest by enrollment, is one of 3 that started in 2012, is one of 9 in phase 3, and was the 5th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

12 of the 29 studies testing iron isomaltoside 1000 in Anemia are open now, in 6 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing iron isomaltoside 1000 in Anemia, or all of them as a file.
02

Study summary

The purpose of the study is to demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is superior compared to placebo with respect to increasing the haemoglobin level in non-anaemic patients undergoing cardiac surgery

Read the detailed description

The role of preoperative haemoglobin as a predictor of short-term and long-term outcomes after cardiac surgery has been well established. Anaemia can impede a patient's ability to recover fully and participate in postoperative rehabilitation. It has been found that patients with a normal haemoglobin level may become anaemic during surgery. An evaluation of patients undergoing cardiac surgery, i.e. CABG, valve or combined CABG-valve procedures showed that there was a decrease in mean haemoglobin level pre-surgery two and four days after surgery. To date, no prospective randomised clinical study in cardiac surgery assessing the effect of intravenous iron supplementation in patients undergoing cardiac surgery has been reported. This prospective, randomized, placebo controlled, double blind study is planned to evaluate the effect of intravenous iron isomaltoside 1000 (Monofer®) in comparison with placebo in non-anaemic patients undergoing cardiac surgery.

03

Conditions studied

  • Non-anaemic Patients Undergoing Cardiac Surgery

Browse trials for

Keywords

  • Anaemia
  • Cardiac surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women, aged more than 18 years.
  2. Subjects undergoing elective or sub-acute CABG, valve replacement or a combination thereof
  3. Female ≥ 12.0 g/dl (7.45 mmol/l), Male Hb ≥ 13.0 g/dl (8.1 mmol/l).
  4. Willingness to participate after .

Exclusion criteria

Exclusion Criteria:

  1. Subjects receiving blood transfusion less than 30 days before screening and/or during the elective or sub-acute CABG, valve replacement, or a combination thereof.
  2. Iron overload or disturbances in utilization of iron (e.g. haemochromatosis and haemosiderosis).
  3. Serum Ferritin > 800 ng/ml.
  4. Known to any in the drug products.
  5. Patients with a history of multiple allergies.
  6. Decompensated liver cirrhosis and hepatitis.
  7. (ALT) > 3 times normal upper value.
  8. Acute infections (assessed by clinical judgement).
  9. Rheumatoid arthritis with symptoms or signs of active joint inflammation.
  10. Pregnant or nursing. (To avoid pregnancy, women have to be (at least 12 months must have elapsed since last menstruation), surgically sterile, or women of child bearing potential must use one of the following during the whole study period and after the study has ended for at least 5 times plasma biological half-life of the investigational medicinal product: Contraceptive pills, Intrauterine Devices (IUD), contraceptive depot injections (prolonged-release gestagen), subdermal implantation, vaginal ring, and transdermal patches).
  11. Participation in any other clinical trial where the study drug has not passed five half-lives prior to screening.
  12. Untreated Vitamin B12 or folate deficiency.
  13. Other IV or oral iron treatment within 4 weeks prior to screening visit.
  14. Erythropoietin treatment within 4 weeks prior to screening visit
  15. Impaired renal function defined by se-creatinin > 150 µmol/l
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Active comparator
    Iron isomaltoside 1000 (Monofer®)

    Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion

    Drug: Iron isomaltoside 1000 (Monofer®)

  • Placebo comparator
    0,9% sodium saline

    Placebo (0.9% sodium saline) - Intravenous infusion

    Drug: Natriumklorid 9 mg/ml, Fresenius Kabi

Interventions

  • All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes

  • DrugNatriumklorid 9 mg/ml, Fresenius Kabi

    All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.

    Also known as: 0.9% sodium chlorid.

06

What researchers measure

Primary outcomes

  1. Change in haemoglobin (Hb) concentrations

    To demonstrate that intravenous iron isomaltoside 1000 (Monofer®) is superior compared to placebo with respect to increasing the haemoglobin level in non- anaemic patients undergoing cardiac surgery

    Time frame: From t=0 to t=4 weeks postoperatively

Secondary outcomes

  1. Change in Hb concentrations

    Proportion of patients that are anaemic (women \< 12 g/dL and men \< 13 g/dL) at day 5 and week 4

    Time frame: t=0, t=5 days and t=4 weeks

  2. Number of patients in each randomisation group who need blood transfusion and number of transfusions administered

    To compare the number of patients who will need blood transfusion and number of transfusions in each randomisation group

    Time frame: From t=0 to t=day 5 and t=4 weeks

  3. Change in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes

    From t=0 to t=day 5 and t=4 weeks

    Time frame: Change from baseline (preoperatively- the day before surgery or same day) in concentrations of serum ferritin, serum iron and Transferrin Saturation (TfS) TfS, and reticulocytes at 4 weeks and 3 months postoperatively

  4. Number of postoperative days to discharge

    To compare the number of days to discharge between the 2 randomisation groups

    Time frame: From t=0 to discharge

  5. Changes in New York Heart Association (NYHA) classification

    To compare the changes in New York Heart Association (NYHA) classification from baseline to 4 weeks postoperatively

    Time frame: From t=0 to t=4 weeks

  6. Number of patients in each randomisation group who experience any study drug related adverse events (AEs/SAEs/SUSARs)

    To compare the number of study drug related adverse events (AEs/SAEs/SUSARs) between subjects treated with iron isomaltoside 1000 (Monofer®) infusion and subjects treated with placebo infusion

    Time frame: From screening and until completion (t=-7 day and upto t=4 weeks)

  7. Change in Hb

    Proportion of patients able to maintain Hb between 9.5 and 12.5 g/dL (both values included) at day 5 and week 4

    Time frame: t=0, t=day 5 and t=week 4

07

Study locations

1 site
  • Copenhagen, Denmark
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Aug 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2012
First posted
Mar 27, 2012
Start
Jan 2012
Primary completionActual
Aug 2013
CompletionActual
Sep 2013
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01563367
Lead sponsor
Pharmacosmos A/S
Collaborators
CRO Max Neeman
Responsible party
Sponsor
First posted
Mar 27, 2012
Start date
Jan 2012
Primary completion
Aug 2013
Completion
Sep 2013
Last update
Apr 29, 2014

Study contacts

Lars Lykke Thomsen
study chair · Pharmacosmos A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion